Skip to main content

Table 2 Background factors stratified by BMI at the time of liver biopsy

From: Non-invasive predictors of prognosis of Asian patients with histopathologically-confirmed lean nonalcoholic fatty liver disease

 

Lean NAFLDa

Non-lean NAFLDb

P value

n

170

276

 

Age

53 (18–85)

52 (18–87)

0.549

Sex, male (%)

61.2

59.4

0.765

Body mass index (kg/m2)

23.1 (18.1–24.9)

28.7 (25.0–42.4)

< 0.01

History of liver cancer (%)

8.9

5.1

0.119

History on non-liver malignancy (%)

9.5

8.3

0.730

Type 2 diabetes mellitus (%)

23.5

38.4

< 0.01

Dyslipidemia (%)

28.2

37.5

0.051

Hypertension (%)

31.8

52.9

< 0.01

Hyperuricemia (%)

2.9

14.9

< 0.01

Smoking (%)

22.1

22.7

0.906

Albumin (g/dL)

4.1 (2.8–5.4)

4.1 (3.0–6.9)

0.994

Aspartate aminotransferase (IU/L)

36 (12–312)

51 (15–378)

< 0.01

Alanine aminotransferase (IU/L)

53 (13–458)

81 (15–783)

< 0.01

Gamma-glutamyl transpeptidase (IU/L)

72 (11–786)

71 (16–990)

0.672

Hemoglobin (g/dL)

14.5 (6.5–17.5)

14.8 (9.2–18.7)

0.192

Platelet count (× 104/μL)

22.0 (4.0–47.1)

20.8 (5.0–37.7)

0.236

Triglyceride (mg/dL)

130 (31–1088)

145 (52–570)

0.021

Total cholesterol (mg/dL)

196 (101–290)

205 (103–370)

0.350

High-density lipoprotein cholesterol (mg/dL)

47 (22–85)

44 (14–86)

0.227

Low-density lipoprotein cholesterol (mg/dL)

116 (27–218)

124 (31–243)

0.073

Fasting blood sugar (mg/dL)

100 (70–237)

105 (65–287)

< 0.01

Glycated hemoglobin (%)

5.8 (4.4–10.8)

6.0 (4.3–12.6)

0.027

Ferritin (ng/mL)

191 (10–1472)

249 (1–2067)

< 0.01

NAFLD fibrosis score

− 2.415 (− 7.060 to 3.095)

− 1.550 (− 5.481 to 3.394)

< 0.01

Genetic variation

   

 Cases tested, (n)

110

204

 

  PNPLA3 rs738409, GG (%)

41.8

41.7

1.000

  TM6SF2 rs58542926, non CC (%)

26.4

23.5

0.585

  HSD17B13 rs6834314, non AA (%)

56.4

45.7

0.078

Histopathological findings

   

 Cases examined, (n)

170

276

 

  Steatosis 3 (%)c

18.9

29.2

0.018

  Ballooning 2 (%)d

22.5

29.9

0.099

  Lobular inflammation 2–3 (%)e

23.7

44.2

< 0.01

  NAFLD activity score 5–8 (%)

34.9

58.0

< 0.01

  Fibrosis stage 3–4 (%)

22.4

38.4

< 0.01

  1. Data are number of patients or median (range) values
  2. P value by Mann–Whitney U test for continuous parameters and Fisher’s exact test for categorical parameters
  3. aLean NAFLD, BMI < 25.0 kg/m2, bnon-lean NAFLD, BMI ≥ 25.0 kg/m2, cSteatosis 3, steatosis of ≥ 66% of hepatocytes, dBallooning 2, hepatocyte ballooning of many cells, eLobular inflammation 2–3, ≥ 2 foci per 200 × field
Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us